bimekizumab
UCB pharma
['axspa', 'bimekizumab', 'be mobile']
l14 #acr22 bimekizumab be mobile 1 and 2
sustained efficacy to wk52. asas40 in bkz incr from w16 (47% nraxspa, 45% as) to w52 (61%, 58%). efficacy in tnf-naive &amp; tnf-failure.
aes: nasopharyngitis (12% nraxspa, 9% as), uri (9, 6%), candidiasis (7, 6%), covid (7, 2%) 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land